Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VE202 in mild-to-moderate ulcerative colitis
NCT05370885Phase 2Terminated
- Sponsor
- Vedanta Biosciences
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 10
01
Overview
A Phase 2 trial of VE202 in ulcerative colitis (UC), sponsored by Vedanta Biosciences. Started May 2023; status: terminated.
02
Drugs
VE202
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05370885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370885.